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Abstract
Background: We conducted a study in order to determine the usefulness and diagnostic value of International
Autoimmune Hepatitis Group (IAHG) score in non-autoimmune hepatitis (AIH) hepatic disorders as well as in AIH/
overlap syndromes and in cases with coexistence of AIH and other liver diseases.
Methods: We applied the IAHG score in 423 patients with liver diseases excluding patients with AIH, AIH/overlap
syndromes and AIH with concurrent other liver disease namely, patients with chronic hepatitis B (n = 109), chronic
hepatitis C (n = 95), chronic hepatitis D (n = 4), alchoholic liver disease (n = 28), non-alcoholic fatty liver disease (n =
55), autoimmune cholestatic liver diseases (n = 77), liver disorders of undefined origin (n = 32) and with miscellaneous
hepatic disorders (n = 23). 24 patients with AIH associated with any kind of liver disorder including 10 patients with AIH/
overlap syndromes and 14 AIH with concurrent other liver disease were also investigated. 43 patients with AIH consisted
the control group.
Results: The specificity of the score was 98.1% while the sensitivity in unmasking AIH in patients with either AIH/overlap
syndromes or AIH with concurrent other liver diseases was only 50% and 78.6%. In the binary logistic regression model,
the presence of other autoimmune diseases (p < 0.001), the total histological score (p < 0.001) and positivity for
autoantibodies (p < 0.05) were identified as independent predictors for the presnce of AIH/ovea syndromes o AI with
concurren other liver diseass.
Conclusion: The IAHG scoring system has very good specificity for excluding AIH in patients with chronic liver diseases
but not that sensitivity in order to unmask AIH/overlap syndromes or AIH with concurrent other liver diseases. The
presence of other autoimmune diseases or autoantibody markers in the absence of hepatitis viral markers should alarm
physicians for the possible presence of AIH either as "pure" AIH or in association with other liver disorders (AIH/overlap
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syndromes or AIH with concurrent other liver diseases). Under these conditions, liver histology seems essential and it
must always be included in the work up of hepatic patients.
Background
Autoimmune hepatitis (AIH) is a chronic liver disease of
unknown aetiology, characterized by female predomi-
nance, hypergammaglobulinemia, circulating autoanti-
bodies, association with human leukocyte antigens (HLA)
DR3 or DR4 and a favourable response to immunosup-
pression [1-4]. The diagnosis of AIH is based on the
revised descriptive criteria for diagnosis of AIH reported
by the International Autoimmune Hepatitis Group
(IAHG) in 1999 [5].
However, some of the features that may support AIH diag-
nosis, such as elevated serum IgG, the detection of autoan-
tibodies and histologically evident interface hepatitis, can
occur with variable frequency in a wide range of other
liver disorders [6-9]. The problem arising in diagnosis
makes the decision for clinical management difficult as
corticosteroids, which constitute the treatment of choice
in AIH are usually contraindicated in these disorders as
they can induce exacerbation of liver disease in cases of
chronic viral hepatitis (CVH) or may deteriorate the stea-
tosis in cases of non alcoholic fatty liver disease (NAFLD).
Furthermore, the diagnosis and consequently the man-
agement is even more complicated in the presence of AIH/
primary biliary cirrhosis (PBC) or AIH/primary sclerosing
cholangitis (PSC) overlap syndromes as well as in cases
with coincidence of AIH and other liver diseases (CVH,
NAFLD, alcohol consumption, etc).
In an attempt to provide a template for diagnosing AIH in
a quantitative and objective manner the IAHG codified in
1993 and updated in 1999 a scoring system for the diag-
nosis of definite or probable AIH [5,10]. The AIH score
constitutes an objective way for assessing different groups
of patients uniformly by including ten basic parameters as
follows: the gender, the alkaline phosphatase (ALP) to
alanino-aminotransferase (ALT) ratio, the serum globu-
lins or IgG increase, the presence or absence of antinuclear
antibodies (ANA), smooth muscle antibodies (SMA) or
liver kidney micosomal antibodies type 1 (anti-LKM-1),
the presence or absence of antimitochondrial antibodies
(AMA), the presence or absence of hepatitis viral markers,
the history of illicit drug use or alcohol abuse, the histo-
logical findings compatible or not with AIH and the pres-
ence of other autoimmune diseases [5].
The score is mainly used for research purposes in order to
include homogenous population in research projects but
occasionally it can be used also in the clinical practice par-
ticularly for the diagnosis of undetermined chronic liver
diseases. Whether the application of the AIH scoring sys-
tem is useful in cases of AIH/overlap syndromes and fur-
thermore, in cases of AIH with concurrent other liver
disease has not been extensively validated so far. Accord-
ingly, we conducted a study in order to evaluate in a large
cohort of patients with chronic liver diseases the diagnos-
tic value of AIH score in other than AIH hepatic disorders,
in AIH/PBC or AIH/PSC overlap syndromes as well as in
coincidental cases of AIH with other liver diseases, as the
correct diagnosis of such patients is crucial for their proper
management. In addition, we analysed and compared
patients' characteristics of each disease group in an
attempt to find out autoimmune features in patients with
liver diseases of non-autoimmune origin that may ham-
per the correct diagnosis and investigated the factors that
may distinguish patients with AIH/overlap syndromes or
with AIH accompanied by other liver diseases from
patients with diverse non-AIH chronic liver diseases.
Methods
Patients
The medical records of 490 patients with diverse liver dis-
eases for whom complete data for the calculation of the
revised IAHG score were available, were reviewed retro-
spectively with the application of the IAHG scoring sys-
tem. Data were collected at the time of the first admission
of each patient in our department and/or visit to the out-
patient clinic. For patients with more than one biopsy, the
first one was taken into account. All patients in the study
were evaluated in a uniform fashion and diagnosis was
assessed according to conventional criteria, by two inde-
pendent experienced investigators (G.N.D. and K.Z.). The
human research review committee of the University of
Thessaly, Medical School approved the study protocol.
The diagnosis of chronic hepatitis C (HCV) was based on
clinical, laboratory and histologic evaluation as we
described previously [11-13]. Briefly, all HCV patients
included in the study met the following criteria: a) sero-
logic evidence of chronic HCV infection as determined by
the detection of antibodies to HCV (anti-HCV) using a
third-generation enzyme immunoassay at least twice
within six months and b) active virus replication as
defined by the detection of HCV RNA using a polymerase
chain reaction. The diagnosis of chronic hepatitis B (HBV)
and hepatitis D (HDV) was based on clinical, laboratory
and histologic evaluation as described by us previously
[13-16] and according to the recent EASL International
Consensus Conference on Hepatitis B [17].Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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Patients with PBC met the following criteria: elevated
cholestatic enzymes, liver histology with PBC lesions and
positivity for AMA (positive titre ≥ 1:40) detected by indi-
rect immunofluorescence (IIFL) on in-house rodent tissue
substrates and confirmed by a competitive enzyme linked
immunosorbent assay (ELISA) with reference antibody
directed against the E2 subunit of pyruvate dehydrogenase
or of the branched chain keto acid dehydrogenase and by
Western blotting using rat liver mitochondrial fractions
following published protocols [18-22]. The diagnosis of
PSC was based on biochemical or clinical signs of
cholestasis, compatible liver histology, repeatedly AMA
negativity by IIFL, Western blot or ELISA and/or typical
findings on endoscopic retrograde cholangiopancreatog-
raphy (ERCP) or magnetic resonance cholangiography
(MRCP) [20,21]. The diagnosis of NAFLD was based on
the presence of metabolic syndrome, exclusion of other
causes of chronic liver disease (viral, autoimmune, drug
and toxin induced) including alcohol abuse and compat-
ible liver histology [23], while the presence of alcoholic
liver disease (ALD) was documented on the grounds of
history of increased alcohol consumption and compatible
laboratory and histological lesions. Patients with liver dis-
orders of undefined origin as well as with miscellaneous
hepatic disorders were also included in the study. The first
group of patients (n = 32) consisted of subjects with no
confirmed diagnosis, in spite of a thorough clinical and
laboratory investigation including liver biopsy and immu-
noserological assessment. The second group (miscellane-
ous hepatic disorders; n = 23) included patients with
Wilson's disease (n = 3), secondary haemochromatosis (n
= 5), Budd-Chiari syndrome (n = 2), drug-induced hepa-
titis (n = 5), benign liver tumors (n = 5) and one of each
of the following conditions: a1-antithrypsin deficiency,
benign cholestasis of pregnancy and Gilbert's syndrome
(n = 3).
The diagnosis of AIH was based on the abovementioned
revised descriptive criteria reported by the IAHG [5], while
patients with AIH/overlap syndromes fulfilled the criteria
for AIH diagnosis as well as those for the diagnosis of
either PBC or PSC. Specifically, AIH/PBC and AIH/PSC
overlap syndromes were defined by the coexistence of AIH
and PBC or PSC diagnosed either simultaneously or con-
secutively according to previously described criteria [24-
26]. Briefly, patients fulfilled at least two of the three cri-
teria for each disease. AIH criteria: 1) positivity for autoan-
tibodies (ANA, SMA or anti-LKM); 2) elevated serum IgG
levels and 3) liver biopsy showing moderate or severe per-
iportal or periseptal lymphocytic piecemeal necrosis; PBC
criteria: 1) cholestatic biochemical profile 2) positivity for
AMA and 3) histological lesions compatible with PBC;
PSC criteria: 1) cholestatic biochemical profile, 2) specific
cholangiographic features on ERCP or MRCP characteris-
tic of PSC and 3) histological changes characteristic of
PSC. The diagnosis of coincidental existence of AIH and
CVH, NAFLD or ALD was based on the descriptive criteria
for AIH diagnosis [5,10] along with those for CVH,
NAFLD and ALD as mentioned above [9,20]. In particu-
lar, the diagnosis of cases with AIH and concurrent CVH
was based on the criteria described by us previously [9,11-
16,20]. In brief, all these cases had serologic and virologic
evidence of HBV, HCV or HDV infections, while they had
increased levels of aminotransferases with normal choles-
tatic enzymes, diffuse hypergammaglobulinaemia, detect-
able ANA, SMA or anti-LKM in high titres, seronegativity
for AMA, absence of other aetiological factors such as,
alcohol consumption or use of known hepatotoxic drug
and a liver biopsy with characteristic lesions of AIH [5,10].
The 490 patients of the study were divided into three
groups:
i). Patients with several liver diseases excluding AIH, AIH/
overlap syndromes and coexistence of AIH with other
liver diseases (n = 423). This group included 109 patients
with chronic HBV infection, 95 with chronic HCV infec-
tion, 4 with chronic HDV infection, 28 with ALD, 55 with
NAFLD, 51 with PBC, 26 with PSC (totally 77 patients
with autoimmune cholestatic liver diseases; ACLD), 32
with liver disorders of undefined origin and 23 patients
with miscellaneous hepatic disorders.
ii). Patients with AIH associated with any kind of liver dis-
order (n = 24) including 7 patients with AIH/PBC, 3 with
AIH/PSC (totally 10 patients with AIH/overlap syn-
dromes), 4 with AIH/chronic HBV infection, 3 with AIH/
chronic HCV infection, 1 with AIH/chronic HDV infec-
tion, 4 with AIH/NAFLD and 2 patients with AIH/ALD
(totally 14 patients with coincidence of AIH and other
liver disease).
iii). Patients with AIH (n = 43), which constitute the dis-
ease control group.
Serum levels of ALT, g-glutamyl-transpeptidase (g-GT),
ALP, IgG and γ-globulins were determined using standard
techniques. ANA, SMA, anti-LKM and AMA were detected
by IIFL on HEp-2 cells and rat liver-kidney-stomach cryo-
stat sections using standard protocols and accepting titers
≥ 1:40 as positive in all cases [4,27-31]. For statistical rea-
sons patients were divided into two groups [positive
(pos)/negative (neg)] for each of the following parameters
of the scoring system: ALP/ALT ratio (pos: score +2, neg:
score 0 or -2), serum γ-globulins or IgG above the upper
normal limit (pos: score ≥ 1, neg: score 0), detection of
ANA, SMA or anti-LKM (pos: titre ≥ 1:40), total score from
the evaluation of liver biopsy (pos: score ≥ 1, neg: score -
11 to 0).Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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Statistical analysis
Results are expressed as mean ± SD. Data were analysed by
x2 (two-by-two with Yate's correction), Fisher's exact test,
Mann-Whitney U-test (MWU), Kruskal-Wallis test and
Spearman's rank correlation (r), where applicable. The
variables significant in the univariate analysis entered a
binary logistic regression model. Two-sided p values less
than 0.05 were considered statistically significant. Confi-
dence intervals (95% CI) were determined using the for-
mula P = p ± 1.96 (pq/n)1/2 where p is the frequency, q is
1-p and n is the number of individuals tested from each
group. The Documenta Geigy Scientific Table (Ciba-Geigy
Ltd, Basle, Switzerland, 1972 7th edition) was used for
95% CI when fewer than 41 individuals were tested.
Results
The relevant demographic, clinical, biochemical, serolog-
ical, and histological data required for the calculation of
the revised IAHG score in the study population are shown
in Table 1.
Specificity and sensitivity of IAHG score
The overall specificity (correctly negative/correctly nega-
tive + false positive) of the revised IAHG scoring system
for the diagnosis of AIH in the context of the presence of
another liver disease was 98.1% (95% CI: 96.8–99.4%)
(Table 2). In more detail, the specificity of the revised
IAHG scoring system for each liver disease was: 99.1%
(95% CI: 97.3–100%) in HBV, 98.9% (95% CI: 97–
100%) in HCV, 96.4% (95% CI: 91.5–100%) in NAFLD,
96.1% (95% CI: 90.7–100%) in ACLD namely 98% (95%
CI: 93–100%) in PBC and 92.3% (95% CI: 82.1–100%)
in PSC, 96.9% (95% CI: 90.9–100%) in patients with
liver disorders of undefined origin and 100% in patients
with ALD, HDV and miscellaneous hepatic disorders
(Table 2).
Only 8 out of 423 patients had an AIH score between 10
and 15 (probable AIH), while none of these patients had
a score above 15 (definite AIH). During a follow-up
period of 30–52 months, 7 patients did not develop other
features supportive of AIH diagnosis, while they
responded favourably to the treatment given according to
their original diagnosis. The eighth patient that was classi-
fied initially as liver disorder of undefined origin has been
lost in follow-up.
The sensitivity (correctly positive/correctly positive + false
negative) of the revised IAHG scoring system for detecting
AIH in association with any kind of other liver disease (n
= 24) was 66.7% (95% CI: 44.7–84.4 %) with 8 out of 24
patients (3 with AIH/PBC, 2 with AIH/PSC, 1 with AIH/
ALD, 1 with AIH/HBV and 1 with AIH/HCV) achieving
aggregate score <10. The remaining 16 patients (4 with
AIH/PBC, 1 with AIH/PSC, 1 with AIH/ALD, 4 with AIH/
NAFLD, 3 with AIH/HBV, 1 with AIH/HDV and 2 with
AIH/HCV) had an AIH score between 10 and 15. In more
detail, the sensitivity of the score for detecting AIH in
patients with AIH/PBC or AIH/PSC overlap syndromes (n
= 10) was 50% (95% CI: 19–81%) with 5 out of 10
patients with AIH/overlap syndromes achieving score
<10. However, the score was more sensitive in the detec-
tion of the coincidence of AIH and other liver disease (n =
14): 78.6% (95% CI: 57.7–100%) with only 3 out of 14
patients achieving score <10.
Parameters that associated with increased AIH score in 
patients with chronic liver diseases (n = 423)
In the univariate analysis, parameters that significantly
differed between patients with liver diseases achieving
AIH score between 10 and 15 (n = 8) and those having a
negative score (aggregate score less than 10; n = 415) were
as follows: a) positive (≥1) score in liver biopsy (p =
0.015) and b) total score from the biopsy (p < 0.001)
(Table 3). After binary logistic regression analysis we
found that the total histological score obtained from liver
biopsy, was the only independent factor that significantly
associated (p = 0.003) with a probable AIH score in non-
AIH patients with chronic liver diseases. Finally, the aggre-
gate score was significantly higher in the group of patients
with probable score compared to those achieving a nega-
tive AIH score (11.63 ± 1.19 vs 2.29 ± 4.07; p < 0.001;
Table 3).
Comparisons between groups
In total (n = 24), patients with AIH/overlap syndromes
and AIH with concurrent other liver diseases had signifi-
cantly more frequently a positive score (≥1) in liver biopsy
(p < 0.001), higher total histological score (p < 0.001),
higher frequency of a positive score for serum globulin or
IgG increase (p = 0.035) and higher frequency of concur-
rent autoimmune diseases (p = 0.001) compared to those
with liver diseases other than AIH (n = 423; Table 4). In
addition, patients with AIH/overlap syndromes and AIH
with concurrent other liver diseases (n = 24) tended to
have more frequently autoantibodies detection compared
to those (n = 423) with liver diseases other than AIH (p =
0.06; Table 4). However, when the variables, which were
significant in the univariate analysis, entered the binary
logistic regression model, the total histological score (p <
0.001), the seropositivity for autoantibodies (p < 0.05)
and the presence of other autoimmune diseases (p <
0.001) were identified as independent predictors for the
presence of AIH associated with any kind of other liver
disorders.
After comparisons of the parameters of IAHG score
among the group of patients with chronic liver disorders
other than AIH (n = 423), the group of patients with AIH/
overlap syndromes (n = 10) and the group of patientsJournal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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with coexistence of AIH and other liver disease (n = 14)
we found that (Table 5): (a) patients with AIH/overlap
syndromes had significantly increased prevalence of AMA
detection (p = 0.02), lower prevalence of viral hepatitis
markers (p = 0.002), lower average alcohol intake (p =
0.07) and higher frequency of concurrent autoimmune
diseases (p = 0.0005) compared to the group of patients
with chronic liver disorders other than AIH; (b) patients
with coincidence of AIH and other liver disease had signif-
icantly more frequently a positive score (≥1) in liver
biopsy (p = 0.0005) and significantly higher total histo-
logical score (p = 0.0005) compared to the group of
patients with chronic liver disorders other than AIH and
(c) patients with AIH/overlap syndromes had significantly
higher prevalence of AMA detection (p = 0.02), lower
prevalence of viral hepatitis markers (p = 0.006) and
lower total histological score (p = 0.01) compared to
patients with AIH concurrent with other liver diseases.
However, after binary logistic regression analysis the pres-
ence of other autoimmune disease was identified as the
only independent predictor for the presence of AIH/over-
lap syndromes (p = 0.001) while the total histological
score from liver biopsy was identified as the only inde-
pendent predictor for the coexistence of AIH and other
liver disease (p < 0.001).
Patients with AIH/overlap syndromes and coexistence of
AIH with other liver diseases (n = 24) were significantly
more frequent of male gender (50% vs 23.3%; p = 0.025),
had higher frequency of a negative score (≤0) in liver
biopsy (45.8% vs 18.6%; p < 0.02), higher frequency of
AMA positivity (16.7% vs 0%; p < 0.02), higher preva-
lence of viral hepatitis markers (33.3% vs 0%; p < 0.001)
and lower total histological score (0.38 ± 3.72 vs 2.73 ±
1.98; p = 0.004) compared with patients suffering from
AIH (n = 43). However, the binary logistic regression anal-
ysis showed that male gender was the only independent
factor that was able to differentiate the coexistence of AIH
with any kind of liver disorder from the presence of iso-
lated AIH (p = 0.025).
Table 1: Patients' characteristics.
Parameters Patients with liver diseases* 
(n = 423)
Patients with coincidence of 
AIH and any kind of liver 
disorder (n = 24)**
Patients with AIH/overlap 
syndromes (n = 10)
Patients with coincidence of 
AIH and other liver disease 
(n = 14)
Patients with AIH 
(n = 43)
Gender (F/M) 231/192 12/12 5/5 7/7 33/10
Age mean ± SD (years) 51.6 ± 22.7 54.9 ± 18.6 49.6 ± 21.6 57.7 ± 15.5 52.3 ± 15.7
Serum globulin or IgG above normal 
(pos/neg; pos = score ≥ 1)
202/221 17/7 7/3 10/4 34/9
Alcohol abuse (>60 g/day: yes/no) 98/325 3/21 0/10 3/11 1/42
Drug use (yes/no) 25/398 0/24 0/10 0/14 1/42
Other autoimmune diseases (yes/
no)
24/399 7/17 5/5 2/12 18/25
ANA or SMA or anti-LKM (pos/neg) 
(positive titre ≥ 1:40)
335/88 23/1 9/1 14/0 43/0
AMA (pos/neg) 49/374 4/20 4/6 0/14 0/43
Histology (pos/neg) (pos = score > 
0, neg = score ≤ 0)
58/365 13/11 3/7 10/4 35/8
Total histologic score ± SD -4 ± 3.3 0.38 ± 3.72 -2.1 ± 4.4 2.14 ± 1.7 2.73 ± 1.98
Median (range) -5 (-11 to +5) 1 (-8 to +4) 0 (-8 to +4) 3 (0 to +4) 3 (-3 to +5)
Abbreviations are same as in text. *Excluding AIH patients (n = 43) and patients with coincidence of AIH and any kind of liver disorder (n = 24); **Means the coexistence of 
AIH with any kind of other liver disease; M = male; F = female.
Table 2: Specificity of the IAHG scoring system.
Patients with liver diseases* (n = 423) Specificity
HBV (n = 109) 108/109 (99.1)
HCV (n = 95) 94/95 (98.9)
HDV (n = 4) 4/4 (100)
ALD (n = 28) 28/28 (100)
NAFLD (n = 55) 53/55 (96.4)
ACLD (n = 77) 74/77 (96.1)
PBC (n = 51) 50/51 (98)
PSC (n = 26) 24/26 (92.3)
Liver disorders of undefined origin (n = 32) 31/32 (96.9)
Miscellaneous hepatic disorders (n = 23) 23/23 (100)
Overall specificity: 415/423 (98.1%)
Abbreviations are same as in text. *Excluding AIH patients (n = 43) and patients with coincidence of AIH and any kind of liver disorder (n = 24).Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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After comparisons of the parameters of IAHG scoring sys-
tem among the group of patients with AIH (n = 43), the
group of patients with AIH/overlap syndromes (n = 10)
and the group of patients with coexistence of AIH and
other liver disease (n = 14) we found that (Table 6): (a)
patients with AIH/overlap syndromes had significantly
increased prevalence of AMA detection (p = 0.001), more
frequently a negative score (≤0) in liver biopsy (p =
0.003), and significantly lower total histological score (-
2.1 ± 4.4 vs 2.73 ± 1.98, p = 0.001) compared to patients
with AIH and (b) patients with coincidence of AIH and
other liver disease had significantly higher prevalence of
viral hepatitis markers (p < 0.001) and higher average
alcohol intake (p < 0.05) compared to AIH patients. How-
ever, after binary logistic regression analysis the lower
total histological score was the only independent predic-
tive factor that was able to differentiate the presence of
AIH/overlap syndromes from the presence of isolated AIH
(p < 0.05), while the higher average alcohol intake was the
only independent predictive factor that was able to differ-
entiate the presence of AIH with concurrent other liver
disease from the presence of isolated AIH (p = 0.02).
The aggregate IAHG score in the group of patients with
coexistence of AIH and any kind of liver disease was sig-
nificantly higher (10 ± 4.1; n = 24) compared to that
found in patients with liver diseases after the exclusion of
AIH patients, patients with AIH/overlap syndromes and
patients with coincidence of AIH and other liver disease
(2.5 ± 4.23; n = 423; p < 0.001; Table 4 and Figure 1) but
significantly lower than the aggregate AIH score observed
in patients with AIH (10 ± 4.1 vs 17 ± 3.05, respectively; p
< 0.001, Figure 1). The aggregate IAHG score for each sub-
group of patients with AIH/overlap syndromes (9.3 ± 4.8;
n = 10) and patients with coincidence of AIH and other
liver disease (10.5 ± 3.7; n = 14) was significantly higher
Table 3: Comparisons of the parameters of the IAHG scoring system between patients with chronic liver diseases* achieving a 
probable (n = 8) and a negative AIH score (n = 415).
Characteristics Negative score no. of patients (%) Probable score no. of patients (%) P-value
Gender
Female 225 (54.2) 6 (75) NS
Male 190 (45.8) 2 (25)
ALP/ALT ratio
Positive: score +2 330 (79.5) 8(100) NS
Negative: score 0, -2 85 (20.5) 0
Serum globulin or IgG above 
normal
Positive (score ≥ 1) 196 (47.2) 6 (75) NS
Negative (score 0) 505 (57.9) 2 (25)
ANA, SMA or anti-LKM
Positive (titre ≥ 1:40) 327 (78.8) 8 (100) NS
Negative 88 (21.2) 0
AMA
Positive (titre ≥ 1:40) 48 (11.6) 1 (12.5) NS
Negative 367 (88.4) 7 (87.5)
Hepatitis viral markers
Yes 214 (51.6) 2 (25) NS
No 201 (48.4) 6 (75)
History of illicit drug use
Yes 25 (6) 0 NS
No 390 (94) 8 (100)
Average alcohol intake
<25 g/day 318 (76.6) 7 (87.5) NS
>60 g/day 97 (23.4) 1 (12.5)
Histological score
Positive (score > 0) 54 (13) 4 (50) 0.015**
Negative (score ≤ 0) 361 (87) 4 (50)
Aggregate histological score (mean 
± SD)
-4.13 ± 3.3 0.88 ± 2.8 <0.001***
Other autoimmune disease
Yes 23 (5.5) 1 (12.5) NS
No 392 (94.5) 7 (87.5)
Aggregate AIH score (mean ± SD) 2.29 ± 4.07 11.63 ± 1.19 <0.001***
Abbreviations are same as in text; NS: not statistically significant; SD: standard deviation; *Excluding AIH patients (n = 43) and patients with 
coincidence of AIH and any kind of liver disorder (n = 24); **Fisher's exact test; ***Mann-Whitney U test;Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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compared to that found in patients with chronic liver dis-
eases (2.5 ± 4.23; n = 423; p < 0.001; Figure 1) and signif-
icantly lower than the aggregate AIH score observed in
patients with AIH (17 ± 3.05; n = 43; p < 0.001, Table 6
and Figure 1).
Discussion
The major point arising from the present study is that the
IAHG scoring system is highly specific for excluding AIH
with specificity values ranging between 92.3%–100% but
not so sensitive in order to detect the association of AIH
with any kind of other liver disease. Indeed, the sensitivity
of the score for the detection of either AIH/overlap syn-
dromes or the coincidence of AIH with other liver disor-
ders was rather low (50% and 78.6%, respectively).
Furthermore, we observed that none of these patients with
AIH/overlap syndromes or AIH with concurrent other
liver disorders achieved a score above 15 (definite AIH),
which is in accordance with a very recent report [32].
Therefore, our findings along with the assumption that
the IAHG scoring system has been designed for study pur-
poses only [5] may indicate the need for the development
of a less complicated system for the diagnosis of AIH in
every day use [33].
Among the large spectrum of liver diseases ALD, CVH and
NAFLD are the most frequent entities that are being diag-
nosed in patients with liver disorders. However, their
presence does not exclude by definition, the possibility of
the coexistence of AIH. Under this context, non-organ spe-
cific autoantibodies commonly occur in patients with
CVH [12,27,28,31,34-37], NAFLD [7,38,39] and ALD
[40,41]. Furthermore, histological features similar to that
observed in AIH as the presence of interface hepatitis may
also occur in other liver diseases [8]. In this study, the spe-
cificity of the IAHG scoring system regarding the exclusion
Table 4: Comparisons of the parameters of the IAHG scoring system between patients with chronic liver diseases* (n = 423) and 
patients with coincidence of AIH and any kind of liver disorder (n = 24).
Characteristics Patients with liver diseases* no. of 
patients (%)
Patients with coincidence of AIH and any kind of 
liver disorder no. of patients (%)
P-value
Gender
Female 231 (54.6) 12 (50) NS
Male 192 (45.5) 12 (50)
ALP/ALT ratio
Positive: score +2 338 (79.9) 20 (83.3) NS
Negative: score 0, -2 85 (20.1) 4 (16.7)
Serum globulin or IgG above normal
Positive (score ≥ 1) 202 (47.8) 17 (70.8) 0.035**
Negative (score 0) 221 (52.2) 7 (29.2)
ANA, SMA or anti-LKM
Positive (titre ≥ 1:40) 335 (79.2) 23 (95.8) 0.06***
Negative 88 (20.8) 1 (4.2)
AMA
Positive (titre ≥ 1:40) 49 (11.6) 4 (16.7) NS
Negative 374 (88.4) 20 (83.3)
Hepatitis viral markers
Yes 216 (51.1) 8 (33.3) NS
No 207 (48.9) 16 (66.7)
History of illicit drug use
Yes 25 (5.9) 0 NS
No 398 (94.1) 24 (100)
Average alcohol intake
<25 g/day 325 (76.8) 21 (87.5) NS
>60 g/day 98 (23.2) 3 (12.5)
Histological score
Positive (score > 0) 58 (13.7) 13 (54.2) <0.001**
Negative (score ≤ 0) 365 (86.3) 11 (45.8)
Aggregate histological score (mean ± SD) -4 ± 3.3 0.38 ± 3.72 <0.001****
Other autoimmune disease
Yes 24 (5.7) 7 (29.2) 0.001**
No 399 (94.3) 17 (70.8)
Aggregate AIH score (mean ± SD) 2.5 ± 4.2 10 ± 4.1 <0.001****
Abbreviations are same as in text; NS: not statistically significant; SD: standard deviation; *Excluding AIH patients (n = 43) and patients with 
coincidence of AIH and any kind of liver disorder (n = 24); **Two by two x square after Yates' correction; ***Fisher's exact test; **** Mann-
Whitney U test.Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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of AIH in patients with CVH, ALD and miscellaneous
hepatic disorders was 98.9–100%. These findings demon-
strate that the use of the IAHG scoring system provides a
quite secure tool for the exclusion of AIH in patients with
diverse liver diseases, which is in accordance with the
findings of previous reports in patients with NAFLD, ALD
and CVH [6,7,42].
In the group of ACLD we found that only 3/77 (3.9%) of
patients achieved a probable AIH score. Previous studies
reported the detection of probable or definite AIH score in
7.4% to 23% of PBC or PSC patients [24,43-47]. This dis-
cordance could be attributed to several demographic fac-
tors and differences regarding the genetic background.
However, we believe that the main reason for the low inci-
dence of a probable or definite AIH score among Greek
PBC and PSC patients is rather due to the design of our
study as in order to investigate the specificity of the score,
we studied patients with PBC or PSC and features of AIH
as a separate group (patients with AIH/overlap syn-
dromes).
It is of interest that the aggregate AIH score was signifi-
cantly lower in patients with AIH associated with any kind
Table 5: Comparisons of the parameters of the IAHG scoring system among patients with chronic liver diseases* (n = 423), AIH/
overlap syndromes (n = 10) and patients with coincidence of AIH and other liver disease (n = 14).
Characteristics Patients with liver diseases* 
no. of patients (%)
Patients with AIH/overlap 
syndromes no. of patients 
(%)
Patients with coincidence of 
AIH and other liver disease 
no. of patients (%)
P value
Gender
Female 231 (54.6) 5 (50) 7 (50) NS
Male 192 (45.4) 5 (50) 7 (50)
ALP/ALT ratio
Positive: score +2 338 (79.9) 8 (80) 12 (85.7) NS
Negative: score 0, -2 85 (20.1) 2 (20) 2 (14.3)
Serum globulin or IgG above normal
Positive (score ≥ 1) 202 (47.8) 7 (70) 10 (71.4) NS
Negative (score 0) 221 (52.2) 3 (30) 4 (28.6)
ANA, SMA or anti-LKM
Positive (titre ≥ 1:40) 335 (79.2) 9 (90) 14(100) NS
Negative 88 (20.2) 1 (10) 0
AMA
Positive (titre ≥ 1:40) 49 (11.6) 4 (40) 0 0.009**
Negative 374 (88.4) 6 (60) 14(100)
Hepatitis viral markers
Yes 216 (51.1) 0 8 (57.1) 0.005**
No 207 (48.9) 10 (100) 6 (42.9)
History of illicit drug use
Yes 25 (5.9) 0 0 NS
No 398 (94.1) 10 (100) 14 (100)
Average alcohol intake
<25 g/day 325 (76.8) 10 (100) 11 (78.6) 0.013**
>60 g/day 98 (23.2) 0 3 (21.4)
Histological score
Positive (score > 0) 58 (13.7) 3 (30) 10 (71.4) <0.001
**
Negative (score ≤ 0) 365 (86.3) 7 (70) 4 (28.6)
Aggregate histological score (mean ± SD) -4± 3.3 -2.1± 4.4 2.14± 1.7 <0.001
***
Other autoimmune disease
Yes 24 (5.7) 5 (50) 2 (14.3) <0.001
**
No 399 (94.3) 5 (50) 12 (85.7)
Aggregate AIH score (mean ± SD) 2.5 ± 4.23 9.3 ± 4.8 10.5 ± 3.7 <0.001
***
Abbreviations are same as in text; NS: not statistically significant; SD: standard deviation; *Excluding AIH patients (n = 43) and patients with 
coincidence of AIH and any kind of liver disorder (n = 24); **Total x square (comparison amongst the three groups of patients; for statistical 
significance between groups see text of results; subheading Comparison between groups, second paragraph); ***Kruskal-Wallis test (comparison 
amongst the three groups of patients; for statistical significance between groups see text of results, subheading Comparison between groups, second 
paragraph).Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
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of liver disease (n = 24) compared to the respective score
in AIH patients but significantly higher compared to that
found in patients with chronic liver diseases (n = 423).
The same findings observed when AIH/overlap syn-
dromes and AIH concurrent with other liver diseases com-
pared separately with AIH patients (n = 43) and patients
with chronic liver diseases (n = 423), while the aggregate
AIH score did not differ between patients with AIH/over-
lap syndromes and those with coexistence of AIH and
other liver disease (Fig. 1). In addition, we showed that
the total histological score, seropositivity for autoantibod-
ies and the presence of other autoimmune diseases were
independent predictive factors for the presence of AIH in
association with any kind of other liver disorder. Separate
analysis of the two groups showed that the presence of
other autoimmune diseases and the total histological
score were stable independent predictors for the identifi-
cation of the presence of AIH/overlap syndromes and the
coexistence of AIH and other liver disease, respectively.
These findings are in accordance with previous reports
[48] suggesting that the IAHG scoring system does pro-
vides some help for identifying the presence of AIH in
association with any kind of liver diseases.
The presence of liver biopsy as an independent discrimi-
native factor in almost all of our comparisons underlines
its overall significance in the diagnosis of the AIH compo-
nent of the individual case. For these reasons we believe
that the second major point arising from our study is that
the liver biopsy is essential in patients with liver diseases
Table 6: Comparisons of the parameters of the IAHG scoring system among patients with AIH/overlap syndromes (n = 10), 
coincidence of AIH and other liver disease (n = 14) and AIH patients (n = 43).
Characteristics Patients with AIH/overlap 
syndromes no. of patients (%)
Patients with coincidence of 
AIH and other liver disease no. 
of patients (%)
Patients with AIH no. of 
patients (%)
P value
Gender
Female 5 (50) 7 (50) 33 (76.7) NS
Male 5 (50) 7 (50) 10 (23.3)
ALP/ALT ratio
Positive: score +2 8 (80) 12 (85.7) 41 (95.3) NS
Negative: score 0, -2 2 (20) 2 (14.3) 2 (4.7)
Serum globulin or IgG above normal
Positive (score ≥ 1) 7 (70) 10 (71.4) 34 (79.1) NS
Negative (score 0) 3 (30) 4 (28.6) 9 (20.9)
ANA, SMA or anti-LKM
Positive (titre ≥ 1:40) 9 (90) 14 (100) 43(100) 0.055*
Negative 1 (10) 0 0
AMA
Positive (titre ≥ 1:40) 4 (40) 0 0 <0.001*
Negative 6 (60) 14(100) 43 (100)
Hepatitis viral markers
Yes 0 8 (57.1) 0 <0.001*
No 10 (100) 6 (42.9) 43 (100)
History of illicit drug use
Yes 0 0 1 (2.3) NS
No 10 (100) 14 (100) 42 (97.7)
Average alcohol intake
<25 g/day 10 (100) 11 (78.6) 42 (97.7) 0.022*
>60 g/day 0 3 (21.4) 1 (2.3)
Histological score
Positive (score > 0) 3 (30) 10 (71.4) 35 (81.4) 0.005*
Negative (score ≤ 0) 7 (70) 4 (28.6) 8 (18.6)
Aggregate histological score (mean 
± SD)
-2.1 ± 4.4 2.14 ± 1.7 2.73 ± 1.98 0.001**
Other autoimmune disease
Yes 5 (50) 2 (14.3) 25 (58.1) NS
No 5 (50) 12 (85.7) 18 (41.9)
Aggregate AIH score (mean ± SD) 9.3 ± 4.8 10.5 ± 3.7 17 ± 3.05 <0.001*
*
Abbreviations are same as in text; NS: not statistically significant; SD: standard deviation; * Total x square (comparison amongst the three groups of 
patients; for statistical significance between groups see text of results, subheading Comparison between groups, third paragraph); **Kruskal-Wallis test 
(comparison amongst the three groups of patients; for statistical significance between groups see text of results, subheading Comparison between 
groups, third paragraph).Journal of Autoimmune Diseases 2007, 4:3 http://www.jautoimdis.com/content/4/1/3
Page 10 of 12
(page number not for citation purposes)
in whom there is evidence of autoimmunity and absence
of evidence of HBV or HCV markers. Therefore, the close
cooperation between clinicians and expertise hepat-
opathologists in an attempt to unmask the presence of
AIH not only in the typical "pure" cases of AIH but also in
difficult cases of the association of AIH with any kind of
liver disorder seems mandatory.
On the other hand, the lower total histological score and
the higher average alcohol intake were identified as inde-
pendent predictors that were able to differentiate the pres-
ence of AIH/overlap syndromes and the presence of the
coexistence of AIH and other liver disease from the pres-
ence of "pure" AIH, respectively. The latter findings under-
line the similarities of characteristics the two groups share
in comparison with the "pure" cases of AIH making their
discrimination quite difficult. At this point, the IAHG
score works as an aggregation of all factors, and no factor
by itself can contribute to the identification of each dis-
ease group (AIH, AIH/overlap syndromes and coexistence
of AIH and other liver diseases).
Conclusion
We demonstrated that the revised IAHG scoring system
has very good specificity. On the contrary, the score is not
very useful in detecting AIH/overlap syndromes or AIH
with concurrent other liver diseases. Liver histology com-
patible with AIH, presence of other autoimmune diseases
or autoantibody markers should alarm physicians for the
possible presence of AIH either as "pure" AIH or as AIH
with concurrent other liver disorders. Taken together, this
study strongly suggests that liver biopsy must always be
included in the work-up of hepatic patients with various
indices of autoimmune manifestations and absence of
evidence of hepatitis B or C, while the consultation with
an expert liver pathologist is strongly recommended.
However, as the number of our patients with overlap syn-
dromes and those with coincident AIH is relatively small,
our observations should be viewed with caution and need
to be confirmed and tested in further multi-centre pro-
spective studies with larger numbers of patients in order
to define and establish appropriate diagnostic criteria for
unmasking the coexistence of AIH with several other liver
disorders including the AIH/overlap syndromes.
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